Lbp Am Sa Sells 38,396 Shares of Pfizer Inc. $PFE

Key Points

• Lbp Am Sa reduced its holdings in Pfizer Inc. by 9.9%, selling 38,396 shares to end with 348,015 shares worth $8,436,000.
• Despite some investors decreasing their stakes, Vanguard Group Inc. and several others increased their positions, with Vanguard owning over 523 million shares valued at approximately $13.25 billion.
• Pfizer reported a strong quarterly earnings result, with earnings per share of $0.78, surpassing estimates and showing a 10.3% revenue increase compared to the previous year.

Lbp Am Sa lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 9.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 348,015 shares of the biopharmaceutical company's stock after selling 38,396 shares during the quarter. Lbp Am Sa's holdings in Pfizer were worth $8,436,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after buying an additional 4,629,976 shares during the last quarter. Northern Trust Corp increased its position in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after purchasing an additional 3,943,397 shares during the period. Amundi increased its position in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Invesco Ltd. increased its position in Pfizer by 2.8% during the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares during the period. Finally, Deutsche Bank AG increased its position in Pfizer by 7.0% during the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE stock opened at $27.21 on Thursday. The company has a market cap of $154.68 billion, a price-to-earnings ratio of 14.47, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $24.59 and a 200-day moving average of $24.14.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm posted $0.60 EPS. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. UBS Group reissued a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.29.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.